Report
Hyloris Pharma - Exciting new partnership for atomoxetine oral liquid
*This morning, Hyloris Pharma announced the out-licensing of atomoxetine oral liquid to Kye Pharma for the Canadian market.*Exciting news for Hyloris, expanding the commercial scope of its liquid formulation beyond the US. We were unfamiliar with Kye Pharma but given its profile as a Canada HQ'ed-private company with a portfolio focused on neurology and pediatrics among other indications, this player seems to be a good fit.*We have increased our TP to EUR 20.3 (vs EUR 19 before) after the recent approval of Maxigesic® IV by the FDA. Buy reiterated considering the upside to yesterday's closing price and near-term news flow
Underlying
Hyloris Pharmaceuticals
Provider
Degroof Petercam
We are an investment house with Belgian roots founded on more than 150 years of trust.
As a private company owned by long-term committed shareholders, we are independent. Naturally and structurally. Our experts have the knowledge to think and act without bias, and to make decisions that benefit our clients. Today and tomorrow.
David Seynnaeve, PhD
Other Reports on these Companies
Other Reports from Degroof Petercam
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.